Project 04: Molecular Carcinogenesis and Chemoprevention (MCC)

项目摘要-分子致癌和化学预防(MCC) 俄亥俄州立大学分子致癌和化学预防(MCC)项目 由医学博士史蒂文·克林顿和博士理查德·菲舍尔领导的综合癌症中心(OSUCCC)已经 来自22个系和8个俄亥俄州立大学学院(文理、牙科、教育和人文)的48名成员 生态学、食品、农业和环境科学、医学、药学、公共卫生和兽医 医学)。MCC计划将癌症作为一个随时间推移的综合和动态过程进行检查，主要的 关注共同影响癌症发生的遗传和环境之间的界面 卡斯卡德。这种方法为化学预防和饮食干预提供了基础，以减少 减少高危人群的癌症负担，并降低#年癌症的发病率、死亡率和发病率 我们的俄亥俄州集水区(CA)和全国。我们的专业知识延伸到定义基因筛查标准和 咨询以及确定饮食和营养指南，通过公共政策影响全国癌症风险 以及全球范围内。MCC计划的具体目标是：1)致癌：描述遗传学、 生殖系、化学、物理、激素或微生物介质诱导的分子和细胞变化 有助于肿瘤转化和多阶段致癌；2)化学预防：发展和 表征新的癌症化学预防药物并确定它们的有效性、安全性和作用机制 使用最终导致早期人类研究的生化、细胞和临床前模型；以及，3)饮食， 营养和新陈代谢：确定饮食模式、营养成分和生活方式变量 促进或抑制癌症进展过程中的致癌级联反应。MCC计划 成员在2014年1月12日至19年11月30日期间发表了547篇与癌症相关的稿件。其中14%是内部- 程序性(来自MCC计划的多名作者)，31%是跨计划的(来自多个OSUCCC的作者 计划)，72%是多机构的(来自CC和其他机构的作者)。全面的协作 出版物占83%。MCC计划的资金总额为790万美元，主要用于癌症，其中 70万美元是经过同行审查的，其中包括来自NIH的680万美元直接资金(来自NCI的340万美元)。在过去的五年里，MCC 计划成员共有1,487人参加试验，670人参加干预性试验，817人参加非干预性试验 审判。MCC成员担任俄亥俄州结直肠癌预防倡议的领导人，涉及3651 参与者(3,310名结直肠癌和341名子宫内膜)和Orien全癌症护理，注册人数为50,683人。 MCC计划与OSUCCC的高度优先的交叉研究倡议和未来计划完全结合 补充和加强方案目标，同时促进与其他研究方案和重点的互动 关于1)癌症发生和预防中的代谢特征；2)微生物组和免疫学与 佩洛托尼亚免疫肿瘤研究所倡议；以及3)与癌症工程中心的合作努力。

PROJECT SUMMARY – MOLECULAR CARCINOGENESIS AND CHEMOPREVENTION (MCC) The Molecular Carcinogenesis and Chemoprevention (MCC) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by Steven Clinton, MD, PhD, and Richard Fishel, PhD, has 48 members from 22 Departments and 8 OSU Colleges (Arts and Sciences, Dentistry, Education and Human Ecology, Food, Agriculture and Environmental Science, Medicine, Pharmacy, Public Health, and Veterinary Medicine). The MCC Program examines cancer as an integrated and dynamic process over time, with a major focus on the interface between genetics and the environment that collectively impacts the carcinogenesis cascade. This approach provides a foundation for chemoprevention and dietary interventions to reduce the burden of cancer in high-risk individuals as well as to decrease the incidence, mortality and morbidity of cancer in our Ohio catchment area (CA) and the nation. Our expertise extends to defining standards for genetic screening and counselling as well defining dietary and nutritional guidelines that impact cancer risk through public policy, nationally and globally. The Specific Aims of the MCC Program are: 1) Carcinogenesis: To characterize the genetic, molecular and cellular changes induced by germline, chemical, physical, hormonal or microbiological mediators that contribute to neoplastic transformation and multistage carcinogenesis; 2) Chemoprevention: To develop and characterize novel cancer chemopreventive agents and define their efficacy, safety, and mechanisms of action using biochemical, cellular and preclinical models that ultimately lead to early phase human studies; and, 3) Diet, Nutrition and Metabolism: To identify dietary patterns, nutritional components, and lifestyle variables that enhance or inhibit the carcinogenesis cascade across the continuum of cancer progression. MCC Program members published 547 cancer-relevant manuscripts between 12/01/14 and 11/30/19. Of these, 14% were intra- programmatic (multiple authors from MCC Program), 31% were inter-programmatic (authors from multiple OSUCCC Programs), and 72% were multi-institutional (authors from both CC and another institution). The total collaborative publications is 83%. MCC Program funding stands at $7.9M in overall direct, cancer-focused funding, of which $7.0M is peer-reviewed, including $6.8M direct funding from NIH ($3.4M from NCI). Over the last five years, MCC Program members have accrued 1,487 participants to trials; 670 to interventional trials and 817 to non-interventional trials. MCC members serve as leaders of the Ohio Colorectal Cancer Prevention Initiative involving 3,651 participants (3,310 colorectal and 341 endometrial) and ORIEN Total Cancer Care with enrollment of 50,683.The MCC program is fully integrated with the high priority crosscutting research initiatives of the OSUCCC and future plans complement and enhance programmatic aims while promoting interactions with the other research Programs and focus on 1) metabolic signatures in carcinogenesis and prevention; 2) the microbiome and immunology interface with Pelotonia Institute for Immuno-Oncology initiatives; and 3) collaborative efforts with the Center for Cancer Engineering.